EGFR and non-small cell lung carcinoma: Although unable to estimate a plausible ICER based on the manufacturer’s submission, afatinib was considered to be a reasonable option for first or second-line treatment for patients with EGFR-mutant NSCLC, with exploratory estimates from the Evidence Review Committee of an ICER of £39,300/QALY gained with afatinib compared to pemetrexed/cisplatin in the overall population, and an ICER of £23,700/QALY gained in the non-Asian population based on trial data provided (46).